Skip to main content
Infilbray™ (venglustat) logo
A young woman who is sitting and painting, overlayed with purple light
A young woman who is sitting and painting, overlayed with purple light

Infilbray™ (venglustat) delivers a neurologic breakthrough in GD31,2

What you’ll learn on this page:

  • Infilbray is the first and only therapy to demonstrate neurologic improvement for patients with Gaucher disease type 31
  • Infilbray crosses the blood-brain barrier and remains CNS active, reducing GL-1 and lyso-GL-11
  • Infilbray is administered conveniently with once-daily oral dosing that can be taken with or without food1

Infilbray is the first and only therapy to deliver a neurologic breakthrough in Gaucher disease type 31,2

Approved to treat neurologic manifestations in GD3 patients weighing ≥15 kg.1

Line icon of bars increasing in height in a step-wise manner with an arrow pointing upwards along the bars

Demonstrated neurologic improvement1

Line icon of a brain

Crosses the blood-brain barrier1

Remains CNS active, reducing GL-1 and lyso-GL-1

Purple text reading “1x Daily”

Convenient once-daily oral dosing1

Can be taken with or without food

Infilbray crosses the blood-brain barrier and directly targets the underlying cause of neurologic symptoms1,3

Crosses the blood-brain barrier1
Infilbray can access the brain, enabling it to provide activity in the CNS.

Reduces GL-1 and lyso-GL-11 
Infilbray is a glucosylceramide synthase inhibitor (GCSi) that reduces the synthesis of GL-1 and subsequently lyso-GL-1.

Frequently asked questions

CNS=central nervous system; CSF=cerebrospinal fluid; ERT=enzyme replacement therapy; GCS=glucosylceramide synthase; GCSi=glucosylceramide synthase inhibitor; GD3=Gaucher disease type 3; GL-1=glucosylceramide; LS=least squares; lyso-GL-1=glucosylsphingosine; OLS=ordinary least squares; RBANS=Repeatable Battery for the Assessment of Neuropsychological Status; SARA=Scale for the Assessment and Rating of Ataxia; SE=standard error; SRT=substrate reduction therapy.

Relevant pages to view:

Indication

INFILBRAY (venglustat) is indicated for the treatment of neurological manifestations of Type 3 Gaucher disease (GD3) in patients weighing at least 15 kg. 

Important Safety Information

Warnings and Precautions:
Suicidal Ideation and Behavior:

Suicidal ideation and behavior have been reported in patients with GD3 receiving INFILBRAY and in unapproved populations receiving another formulation of venglustat, both with and without a history of psychiatric disorders. Assess patients' underlying risk of psychiatric disorders prior to initiation and monitor for depressive symptoms or suicidal thoughts during treatment. Use caution when prescribing to patients with a history of psychiatric disorders. Inform patients or caregivers of the potential for behavioral and mood changes and to seek medical attention for manifestations of suicidal ideation and behavior, new onset or worsening depression, or other mood changes. Consider changing the therapeutic regimen, including possibly discontinuing INFILBRAY, if such events occur.

Lens Opacification in Pediatric Patients:

Lens opacification may occur in pediatric patients treated with INFILBRAY. In pediatric patients, perform ophthalmological assessment prior to initiation and annually during treatment. Advise pediatric patients and caregivers to report any visual disturbances during treatment.

Embryofetal Toxicity:

Based on animal studies, INFILBRAY may cause fetal harm when administered to a pregnant woman. Prior to initiation, verify pregnancy status in females of reproductive potential and advise them of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 11 days after the last dose.

Adverse Reactions:
The most common adverse reactions reported in ≥10% of INFILBRAY-treated GD3 patients aged ≥12 years were diarrhea, splenomegaly, nausea, depression, gastroenteritis, and vomiting.


Drug Interactions:
Strong CYP3A Inhibitors: Avoid concomitant use with INFILBRAY. Strong CYP3A inhibitors increase venglustat exposure, which may increase the risk of adverse reactions. If concomitant use is unavoidable, reduce INFILBRAY dosage.

Strong or Moderate CYP3A Inducers: Avoid concomitant use with INFILBRAY. Strong or moderate CYP3A inducers decrease venglustat exposure, which may result in decreased efficacy. If concomitant use is unavoidable, monitor for reduced effectiveness.

Please see Full Prescribing Information for INFILBRAY.

Indication

Important Safety Information

References: 1. Infilbray (venglustat). Prescribing information. Genzyme Corporation, Cambridge, MA. 2. Sanofi. Press release: Sanofi’s venglustat earns breakthrough therapy designation in the US for type 3 Gaucher disease. Accessed October 5, 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-03-18-06-00-00-3257888 3. Grabowski GA et al. The Online Metabolic and Molecular Bases of Inherited Disease. Accessed August 7, 2026. https://ommbid.mhmedical.com/content.aspx?bookid=2709&sectionid=225546056 4. Schiffmann R et al. J Inherit Metab Dis. 2020;43(5):1056-1059. 5. Mistry P et al. Poster presented at: WORLDSymposium; February 2-6, 2026; San Diego, CA.

©2026 Sanofi. All rights reserved. All trademarks mentioned are the property of the Sanofi group. MAT-US-2608184-v1.0-11/2026. Last updated: November 2026.